Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

29d ago, source: Yahoo Finance

NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the ...

Why Is Alzheimer's-Focused Hoth Therapeutics Stock Trading Higher On Tuesday?

1mon ago, source: Hosted on MSN

Tuesday, Hoth Therapeutics Inc (NASDAQ:HOTH) unveiled positive preclinical research showcasing the potential of HT-ALZ, an Alzheimer’s disease therapeutic. Targeting the Substance P/Neurokinin 1 ...

Hoth Therapeutics Stock (NASDAQ:HOTH), Analyst Ratings, Price Targets, Predictions

2mon ago, source: Benzinga.com

Hoth Therapeutics Inc has a consensus price target of $7.5, established from looking at the 12 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., EF Hutton ...

Promising Preclinical Alzheimer’s Candidate and Diverse Pipeline Bolster Hoth Therapeutics’ Buy Rating

20d ago, source: Business Insider

Hoth Therapeutics (HOTH) Company Description: Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform.

Hoth Therapeutics, Inc.: Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

1mon ago, source: Finanznachrichten

NEW YORK, March 19, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative Alzheimer's ...

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

29d ago, source: Stockhouse

NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate ...

Hoth Therapeutics Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...